- New Arrivals
- Hot items
The instruction for medical use
of CHILDREN’S ANAFERON medicine
A trade name
of the drug Anaferon children’s
the International unlicensed name
Is not present
the Dosage form
of the Tablet for resorption
One tablet contains:
active agent: Antibodies to scale to interferon of the person affinely cleaned – 0.003 g*.
excipients: lactoses monohydrate, cellulose microcrystalline, magnesium stearate.
* are applied on lactoses monohydrate in the form of aqueous-alcoholic mix with contents no more than 10-16 ng/g an active form of active ingredient.
of the Tablet of a ploskotsilindrichesky form, with risky and a facet, from white till almost white color. On the flat party from risky the inscription MATERIA MEDICA is put, on other flat party the inscription ANAFERON KID is put.
Antiviral drugs for system use.
Antiviral drugs of direct action.
Antiviral drugs other.
Pharmacokinetics Sensitivity properties of modern physical and chemical methods of the analysis the maintenance of midget doses of antibodies in biological liquids, bodies and fabrics does not allow to estimate the ATX J05AX codes that makes technically impossible studying pharmacokinetics of the drug Anaferon children’s.
Experimentally is also clinically established efficiency concerning influenza viruses, a parainfluenza, viruses of a herpes simplex of 1 and 2 types (labial herpes, genital herpes), others herpes viruses (chicken pox, an infectious mononucleosis), enteroviruses, a virus of tick-borne encephalitis, a rotavirus, a coronavirus, a kalitsivirus, adenovirus, respiratory and syncytial (PC virus). Drug reduces concentration of a virus in the struck fabrics,
influences the system of endogenous interferon and the cytokines interfaced to them, induces formation of endogenous early interferon (IFN and/) and gamma interferon (IFN).
Stimulates the humoral and cellular immune response. Raises products of antibodies (including secretory IgA), activates functions of T-effectors, T-helperov (Tkh), normalizes their ratio. Raises a functional reserve of Tkh and other cells participating in the immune response. Is the inductor of the mixed Txl and Tkh2-tipa of the immune response: increases production of Txl cytokines (IFN, SILT-2) and Tkh2 (IL-4, 10), normalizes (modulates) balance of Tkh1/Tkh2 of activities. Increases functional activity of phagocytes and natural cells killers (EK of cells). Has anti-mutagen properties.
– Prevention and treatment of acute respiratory viral infections (including flu).
– Complex therapy of the infections caused herpes viruses (an infectious mononucleosis, chicken pox, labial herpes, genital herpes).
– Complex therapy and prevention of a recurrence of persistent herpesviridae infection, including labial and genital herpes.
– Complex therapy and prevention of other acute and persistent viral infections caused by a virus of tick-borne encephalitis, an enterovirus, a rotavirus, a coronavirus, kalitsivirusy.
– Use as a part of complex therapy of bacterial infections.
– Complex therapy of secondary immunodeficiency of various etiology, including prevention and treatment of complications of viral and bacterial infections.
Route of administration and doses
Inside. To children 6 years and the adult are more senior: on one reception 1 tablet (to hold in a mouth before full dissolution not during meal).
To children from 1 month to 6 years: when prescribing drug children of younger age (from 1 month to 6 years) are recommended to dissolve a tablet in a small amount (1 tablespoon) of boiled water of room temperature.
SARS, flu, intestinal infections, herpesviridae infections, neuroinfections. Treatment should be begun as soon as possible at emergence of the first symptoms of an acute viral infection according to the following scheme: in the first 2 hours the drug is taken by each 30 minutes, then within the first day carry out three more receptions at regular intervals. From second day and further accept on 1 tablet 3 times a day to an absolute recovery.
In the absence of improvement, for the third day of drug treatment of acute respiratory viral infections and flu it is necessary to see a doctor.
During an epidemic season with the preventive purpose the drug is taken daily once a day within 1-3 months.
Genital herpes. At acute manifestations of genital herpes the drug is taken according to the following scheme at regular intervals: 1-3 day on 1 tablet of 8 times a day, further on 1 tablet 4 times a day not less than 3 weeks.
For prevention of a recurrence of persistent herpesviridae infection on 1 tablet a day. The recommended duration of a preventive course is defined individually and can reach 6 months.
At the use of drug for treatment and prevention of immunodeficiency, in complex therapy of bacterial infections to accept on 1 tablet a day. If necessary drug can be combined with other antiviral and symptomatic means.
When using drug on the specified indications and in the specified dosages of side effects it is not revealed.
Manifestations of the increased individual sensitivity to drug components are possible.
the increased individual sensitivity to drug components, children’s age up to 1 month.
of Cases of incompatibility with other medicines it is not revealed so far.
If necessary drug can be combined with other antiviral, antibacterial and symptomatic agents.
monohydrate in this connection patients are not recommended to appoint it with a congenital galactosemia, a sprue of glucose or in a congenital lactose intolerance is a part of drug lactoses.
Pregnancy and the period of a lactation
Safety of use of Anaferon children’s at pregnant women and in the period of a lactation was not studied. In need of administration of drug it is necessary to consider a ratio risk/advantage.
Features of influence on ability to run the vehicle or other potentially dangerous
Anaferon mechanisms children’s does not influence ability of control of vehicles and other potentially dangerous mechanisms.
of Cases of overdose it is not registered so far.
Symptoms: dispepsichesky phenomena.
A form of release and packing
of the Tablet for resorption. On 20 tablets in blister strip packaging from a film of polyvinylchloride and aluminum foil.
On 1 or 2 blister strip packagings together with the instruction for medical use in the state and Russian languages place in a pack from cardboard.
To Store storage conditions at
a temperature not higher than 25 S. Hranit out of children’s reach.
During the drug use period to store blister strip packaging in the cardboard pack provided by the producer.
A period of storage
not to apply after an expiration date
OOO NPF MATERIA MEDIKA HOLDING producer, Russia, 127473, Moscow, 3rd Samotechny Lane, 9. Ph./fax: (495) 684-43-33.
Owner of the registration certificate
of OOO NPF MATERIA MEDIKA HOLDING, Russia.
The address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products
of Predstavitelstvo OOO NPF MATERIA MEDIKA HOLDING in RK Almaty, Zhibek St. of a zhola 64, office 206.